Citation for published version (APA):

Citing this paper
Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination, volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are again advised to check the publisher's website for any subsequent corrections.

General rights
Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.

•Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
•You may not further distribute the material or use it for any profit-making activity or commercial gain
•You may freely distribute the URL identifying the publication in the Research Portal

Take down policy
If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.
Cannabis affects people differently: inter-subject variation in the psychotogenic effects of Δ⁹-tetrahydrocannabinol: a functional magnetic resonance imaging study with healthy volunteers

Z. Atakan¹*, S. Bhattacharyya¹, P. Allen¹, R. Martín-Santos², J. A. Crippa³, S. J. Borgwardt¹, P. Fusar-Poli¹, M. Seal², H. Sallis⁴, D. Stahl⁶, A. W. Zuardi⁵, K. Rubia⁷ and P. McGuire¹

¹ Section of Neuroimaging, Department of Psychosis Studies, Institute of Psychiatry, King’s College London, London, UK
² Institut Municipal Investigació Medica IMIM Hospital del Mar, Barcelona, Spain
³ Departamento de Neuropsiquiatria e Psicologia Médica, Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Brazil
⁴ Psychiatric Outpatient Department, University Hospital Basel, Basel, Switzerland
⁵ Murdoch Children’s Research Institute, The Royal Children’s Hospital, Parkville, Australia
⁶ Department of Biostatistics, Institute of Psychiatry, King’s College London, London, UK
⁷ Section of Developmental Neuropsychology and Neuroimaging, Institute of Psychiatry, King’s College London, London, UK

Background. Cannabis can induce transient psychotic symptoms, but not all users experience these adverse effects. We compared the neural response to Δ⁹-tetrahydrocannabinol (THC) in healthy volunteers in whom the drug did or did not induce acute psychotic symptoms.

Method. In a double-blind, placebo-controlled, pseudorandomized design, 21 healthy men with minimal experience of cannabis were given either 10 mg THC or placebo, orally. Behavioural and functional magnetic resonance imaging measures were then recorded whilst they performed a go/no-go task.

Results. The sample was subdivided on the basis of the Positive and Negative Syndrome Scale positive score following administration of THC into transiently psychotic (TP; n=11) and non-psychotic (NP; n=10) groups. During the THC condition, TP subjects made more frequent inhibition errors than the NP group and showed differential activation relative to the NP group in the left parahippocampal gyrus, the left and right middle temporal gyri and in the right cerebellum. In these regions, THC had opposite effects on activation relative to placebo in the two groups. The TP group also showed less activation than the NP group in the right middle temporal gyrus and cerebellum, independent of the effects of THC.

Conclusions. In this first demonstration of inter-subject variability in sensitivity to the psychotogenic effects of THC, we found that the presence of acute psychotic symptoms was associated with a differential effect of THC on activation in the ventral and medial temporal cortex and cerebellum, suggesting that these regions mediate the effects of the drug on psychotic symptoms.

Received 17 February 2012; Revised 20 July 2012; Accepted 20 July 2012; First published online 1 October 2012

Key words: Cerebellum, fMRI, middle temporal gyri, parahippocampus, response inhibition, THC.

Introduction
Epidemiological research points towards a link between the use of cannabis and the increased risk of developing a psychotic illness, in a dose-dependent manner (Arseneault et al. 2002; Zammit et al. 2002; Moore et al. 2007). However, cannabis affects individuals differently and not everyone who uses it develops psychosis. The basis of this variable sensitivity is unclear, as is the location where Δ⁹-tetrahydrocannabinol (THC), the main compound of the plant, mediates its psychotogenic effects. Individuals with a predisposition to psychosis who might be particularly vulnerable to its adverse effects were indicated by a positive family history of psychosis (McGuire et al. 1995), a schizotypal personality (Stirling et al. 2008), the presence of subclinical psychotic features (Henquet et al. 2004), being at ultrahigh risk for psychosis (Peters et al. 2009) or carrying specific genes (Caspi et al. 2005; van Winkel et al. 2011; Bhattacharyya et al. 2012a).

Elucidating which behavioural and biological factors confer greater risk for psychosis in cannabis users
is crucial, because as the availability of plants with higher THC content has increased, so have the related health risks (Degenhardt et al. 2010; Cascini et al. 2011). Although relatively few individuals develop a full-blown psychotic illness after cannabis use, a larger number (between 15 and 51%) experience transient psychotic symptoms lasting from a few hours to a few days, as a result of cannabis use (Thomas, 1996; Green et al. 2003; D’Souza et al. 2004, 2009; Morrison et al. 2009). It is not yet known if there is a continuum of risk between those who become transiently psychotic (TP) and those who develop an enduring psychotic illness in relation to cannabis use. However, it would be both logical and ethically feasible to study the effects of THC in healthy individuals by comparing those who experience transient psychotic symptoms due to cannabis intoxication with those who do not. Findings may inform research on the mechanisms underlying psychotic symptoms per se, as well as examining behavioural and neurobiological mechanisms that increase the potential risk to an individual.

Although there are a growing number of neuroimaging studies that have examined the acute effects of THC administration on brain function (Martín-Santos et al. 2010), including those from our group (Borgwardt et al. 2008; Fusar-Poli et al. 2009; Bhattacharyya et al. 2009, 2010; Winton-Brown et al. 2011), to date none of these studies has examined the effects of THC according to psychotic symptom outcome. Response inhibition, the ability to suppress irrelevant acts, is a function that is impaired in cannabis users, since they make more inhibitory errors (Hester et al. 2009; Ramaekers et al. 2009; Battisti et al. 2010a). It is also relevant to patients with schizophrenia who are reported to perform slowly in various response inhibition tasks (Enticott et al. 2008; Huddy et al. 2009) and have poor error awareness (Turken et al. 2003). Furthermore, this group shows abnormal frontostriatal activation during inhibition tasks (Rubia et al. 2001a). A well-established response inhibition paradigm used in imaging studies is the go/no-go task, which involves the activation of the inferior frontal cortex (IFC), dorsolateral prefrontal cortex (DLPFC), inferior parietal cortices and anterior cingulate gyrus (ACG) (Rubia et al. 2001b; Simmonds et al. 2008).

The neuroimaging findings regarding the effect of cannabis on response inhibition are inconclusive due to methodological variations. Two studies report significantly lower activation in regular cannabis users, relative to non-users, within the ACG and diffuse bilateral activity in the DLPFC (Gruber & Yurgelun-Todd, 2005; Hester et al. 2009). Another study reports increased response in the right DLPFC, bilateral medial frontal, inferior and superior parietal lobules in cannabis users even after 28 days of monitored abstinence (Tapert et al. 2007). In our previous study on response inhibition in participants who had seldom used cannabis, but were challenged with oral THC relative to placebo, THC was shown to attenuate activation in the right IFC and ACG and precuneus bilaterally (Borgwardt et al. 2008).

In the present study, we supplemented our previous sample by recruiting additional participants, using exactly the same criteria and methodology, to investigate brain activation in those who experienced transient psychotic symptoms after THC administration, compared with those who did not. The administration of cannabidiol, in addition to THC and placebo, is not included in this paper, as it is not relevant to the investigation in question. We hypothesized that participants who developed transient psychotic symptoms with THC would show differential activation relative to those that did not experience psychotic symptoms in brain regions that have previously been implicated in the pathophysiology of psychosis, such as the prefrontal, medial temporal and ventral temporal cortex.

Method

Design

This was a double-blind, placebo-controlled within-subject study, with a 1-month interval between scans. The order of drug administration was pseudo-randomized so that equal numbers followed each drug sequence. The Joint South London and Maudsley National Health Service and Institute of Psychiatry Research Ethics Committee approved the protocol. Each subject provided informed consent and was given extensive written and verbal information about the effects of cannabis, including psychotic symptoms.

Participants

All 21 participants were healthy, native English-speaking, right-handed males. The majority (90.5%) were white British. Their ages ranged from 20 to 42 years. All of them had used cannabis on no more than 25 occasions in their lifetime and none had used cannabis in the previous 3 months.

Criterion for inclusion into the TP group was made post hoc, on the basis of those who scored 3 or more on at least three items of the Positive and Negative Syndrome Scale (PANSS) positive subscale (Kay et al. 1987) at 2-h measurements. D’Souza et al. (2004), in their THC challenge study, had used the same criterion previously. Participants who scored below these thresholds were classed as ‘non-psychotic’ (NP). We identified 11 who met the criteria for transient
psychosis. All completed the scanning procedure, except for one who became too anxious to stay in the scanner. Therefore, the behavioural and symptomatic data are based on 11 TP participants and the imaging data on 10.

Participants were carefully screened and the details of the procedures can be found in the supplementary material. They were asked to abstain from any illicit drug use during the study period, from alcohol and coffee 24 and 12 h before, respectively, and cigarettes on the morning of each session, as well as receiving a urine drug screening prior to scans.

**Procedure**

Participants were examined at the start of each session and their pulse and blood pressure were monitored. They were given identical-looking red gelatine capsules of either 10 mg of THC (99.6% pure; THC-Pharm, Germany) or placebo (flour). Both participants and researchers were blind to the content of the capsules. The dose of THC was selected on the basis of previous research (Chesher et al. 1990; Curran et al. 2002; Gray et al. 2008) to produce an effect on regional brain activation without prominent intoxication. Even though oral administration is known to indicate erratic absorption and inter-subject variability (Grotenhermen, 2003), it was the preferred method in this study in order to produce a slow peaking plasma level for the duration of the imaging session (Lemberger et al. 1971; Ohlsson et al. 1980).

**Behavioural ratings**

The behavioural effects were evaluated at baseline (before drug administration), +1 h (immediately before scanning), +2 h (immediately after scanning) and at +3 h time points by using the Visual Analogue Mood Scale (VAMS), State-Trait Anxiety Inventory (STAI), Addiction Research Centre Inventory (ARCI), Analogue Intoxication Scale (AIS), Cambridge Depersonalization Scale and PANSS. Further information on these scales is available in the supplementary material.

As the focus of this paper is to explore the differences between those who become TP under THC and those who do not, we mainly evaluated the baseline and 2-h measurements, when the peak intoxication is experienced following oral administration. The 3-h measurements are also presented in the graphs.

Researchers stayed with the participants until all their symptoms disappeared. In all cases symptoms had resolved spontaneously within 2–3 h. No psychological symptoms were reported in follow-up checks the next day, and at 1 week and 1 month later.

**Functional MRI paradigm – go/no-go**

Participants practised the go/no-go task prior to scanning to ensure familiarity. The task involves motor response inhibition and selective attention. Subjects are required to either execute or inhibit a motor response according to the visual cues presented on a screen. The task is described in detail in the supplementary material.

**Behavioural analyses**

Data were recorded on SPSS version 20.0 (SPSS, Inc., USA) and analysed using Stata 11 (StataCorp LP, USA). Descriptive statistics were used to summarize the baseline variables. Age, years of education, and cannabis, cigarette, alcohol and other drug use were compared between the two groups using t tests (or equivalent non-parametric Mann–Whitney U tests or Fisher’s exact test). A multilevel model was used to assess the effect of THC on each outcome measure, with subject included as a random effect and time as a fixed effect. A second multilevel model assessed the difference between the TP and NP groups. The distribution of each measure was assessed and no gross violations of normality were found, thus making transformations of the data unnecessary. Non-parametric methods are not advisable in this situation as they are unable to handle missing data. The multilevel models used in our analysis are less restrictive regarding missingness assumptions.

When investigating task performance, two further multilevel models were run. The first included the main effect of drug only, while group effect and its interaction with drug were also added in the second.

**Image acquisition**

Images were acquired on a 1.5-T Signa (GE, USA) system at the Maudsley Hospital, London. T2*-weighted images were acquired with a repetition time (TR) of 1.8 s, echo time (TE) of 40 ms, flip angle 90° in 16 planes (7 mm thick), parallel to the anterior commissure–posterior commissure line. To facilitate anatomic localization of activation, a high-resolution inversion recovery image dataset was also acquired, with 3-mm contiguous slices and an in-plane resolution of 3 mm (TR 16000 ms, inversion time 180 ms, TE 80 ms).

**Data processing and analysis**

A complete description of image analysis including pre-processing and non-parametric statistical modelling can be found in the supplementary material. A non-parametric approach (XBAM v4; http://www.
Results

Of the 12 participants receiving THC in the first session and placebo in the second, six were classified as being in the TP group. The order of drug administration was reversed in the remaining nine participants, of whom five were subsequently included in the TP group. There was no evidence of an order effect, and no significant group differences with respect to age or years of education (all p > 0.1). Out of 21, 13 did not smoke. A total of eight participants were current tobacco smokers, but only two smoked more than 10 cigarettes per day and both of these were in the NP group. Fisher’s exact test showed no significant difference between the two groups in terms of cigarette smoking, cannabis, alcohol and other drug use (all p > 1.00) (Table 1).

Symptom data

In all participants, a significant change in the level of the following outcome measures was observed 2 h after the administration of THC: STAI (p < 0.001), ARCI (p < 0.001), VAMS tranquillization subscale (p = 0.007), AIS (p < 0.001) and each of the PANSS subscales (p ≤ 0.001) (Fig. 1). For each of these measures an increase in score was observed, with the exception of VAMS tranquillization, which was lower at 2 h. The differences observed between baseline and 2 h were only significant when participants received THC, rather than placebo.

There was no significant difference between the TP and NP groups on any symptom measure at baseline or after placebo administration. However, 2 h after the administration of THC, there was a significant difference between the groups for VAMS tranquillization (p = 0.031), PANSS negative (p = 0.020) PANSS positive, general and total subscales (all p ≤ 0.001); no significant difference was found for the other behavioural scales (Table 2, Fig. 2).

Physiological measures

Under the THC condition, there was no evidence of a difference in heart rates between the two groups either at baseline or 2 h after drug administration. However, when looking at the effect of the drug across all participants, heart rate was significantly increased at 2 h after administration of either THC (p ≤ 0.001) or placebo (p = 0.002). There were no significant differences between either systolic or diastolic blood pressure in the two groups either at baseline or 2 h after administering THC. Graphs of physiological measures are provided in the supplementary material.

Task performance

There was a non-significant trend suggesting that THC increased inhibition errors among all participants (p = 0.066). A significant interaction was found between group and drug condition (p = 0.002). Inhibition errors were significantly higher in the TP group than in the NP group (p < 0.001), but only when participants received THC. No significant differences were found for mean reaction time to ‘go’ trials between the THC and placebo conditions. A table on task performance is provided in the supplementary material.

Neuroimaging results

Task effect

Under the placebo condition, no-go relative to oddball trials were associated with activation in the right ACG, prefrontal cortex and right middle temporal gyrus (MTG) independent of group, but with a less conservative significance threshold contrast (p < 0.025; uncorrected for <1 false-positive cluster).

Main effect of drug

During no-go compared with oddball trials, across all subjects, THC increased activation in the hippocampus, the tail of the caudate nucleus and the insula in the right hemisphere, relative to placebo. There were no areas where THC was associated with reduced activation relative to placebo.
Main effect of group

During no-go compared with oddball trials, independent of drug, the TP group showed less activation than the NP group in the right MTG ($p < 0.005$; corrected for $<1$ false-positive cluster) and the vermis of the cerebellum ($p < 0.005$; corrected for $<1$ false-positive cluster). There were no areas where the TP group showed greater activation than the NP group (Fig. 3).

Group × drug interaction

There was a significant interaction ($p < 0.01$; corrected for $<1$ false-positive cluster) between the effects of drug and group in the left parahippocampal gyrus (PHG), MTG, superior temporal gyrus (STG) and in the region spanning the right cerebral and adjacent fusiform gyrus. In all of these regions, relative to placebo, THC significantly attenuated activation in the TP group, whereas it increased it in the NP group.

Discussion

We used functional magnetic resonance imaging to investigate differential response to oral THC in a group of healthy, seldom cannabis users and compared the behavioural and imaging findings of those who developed transient psychotic symptoms with those who did not. We found significant differences between the two groups in the effects of THC in the left PHG, STG, MTG and cerebellum, where THC decreased activation in TPs, but increased it in NPs. In the right MTG the reverse happened; THC increased activation in the TPs and decreased it in the NPs. This was accompanied by a higher error rate in the TPs, relative to the NP group, during THC condition. TPs also showed less activation than the NPs in the right MTG.

| Table 1. Participants’ sociodemographic and substance-use comparisons$^a$ |
|---------------------------------|-------------------------------|
|                                 | Transiently psychotic ($n = 11$) | Non-psychotic ($n = 10$) |
| THC in first session, $n$       | 6                              | 6                           |
| Mean age, years (±d)           | 26.76 (5.00)                   | 25.70 (6.27)                |
| Mean education, years (±d)     | 15.33 (3.64)                   | 16.78 (4.15)                |
| Employment, $n$ (%)             |                                 |                             |
| Employed                       | 8 (72.7)                       | 3 (30.0)                    |
| Unemployed                     | 0 (0)                          | 1 (10.0)                    |
| Student                        | 2 (18.2)                       | 5 (50.0)                    |
| No details                     | 1 (9.1)                        | 1 (10.0)                    |
| Cannabis use$^b$, $n$ (%)       |                                 |                             |
| Experimental                   | 7 (63.6)                       | 5 (50.0)                    |
| Occasional                     | 4 (36.4)                       | 5 (50.0)                    |
| Cigarette use, $n$ (%)          |                                 |                             |
| Non-smoker                     | 7 (63.6)                       | 6 (60.0)                    |
| Smoker                         | 4 (36.4)                       | 4 (40.0)                    |
| Alcohol use$^c$, $n$ (%)        |                                 |                             |
| Occasional                     | 6 (54.6)                       | 5 (50.0)                    |
| Moderate                       | 5 (45.4)                       | 5 (50.0)                    |
| Other drugs, $n$ (%)            |                                 |                             |
| Not used                       | 8 (72.7)                       | 7 (70.0)                    |
| Used                           | 3 (27.2)                       | 3 (30.0)                    |

THC, D$^9$-Tetrahydrocannabinol; ±d, standard deviation; df, degrees of freedom.

$^a$ No order effect ($\chi^2 = 0.06$, df = 1, $p = 0.80$) and no significant group differences with respect to age (Mann–Whitney U test: $Z = -0.78$, $p = 0.44$), years of education ($t = 0.79$, df = 16, $p = 0.44$) and with Fisher’s exact test: use of cigarette smoking ($p = 1.00$), cannabis ($p = 0.67$), alcohol ($p = 1.00$) and other drug use ($p = 1.00$).

$^b$ Experimental cannabis use = less than 10 times. Occasional use = 10–25 times, in lifetime.

$^c$ Occasional alcohol use = drinking at weekends, social events. Moderate use = drinking at least three times per week.

Relative to placebo, THC also increased activation in the right MTG in the TP group ($p < 0.01$; corrected for $<1$ false-positive cluster), but it attenuated activation in the NP group (Fig. 4).
MTG and the vermis of the cerebellum, independent of THC.

**Symptomatic effects of THC**

As the groups were defined in terms of their psychotic experiences following THC, it is not surprising that they differed in their PANSS scores. Due to the small sample size, however, formal corrections for multiple testing were not possible. Instead we lowered the significance level from 5% to 1% at which the PANSS positive, general and total scores remained significant, and the negative subscale showed a trend \((p = 0.02)\). Therefore the negative scale result needs to be treated with caution. Even though THC significantly affected most measures in all participants, there were remarkably few significant differences in the levels of mood, anxiety and intoxication between the two groups. This may suggest that the differential sensitivity to the effects of THC was particularly and specifically related to psychotic symptoms. We cannot exclude the possibility that the absence of differences between the two groups in NP symptoms was due to limited statistical power. However, that seems unlikely, as the groups differed significantly not just on psychotic symptom severity, but also in terms of another behavioural measure: response inhibition errors.

In terms of the acute effects of THC, our findings are in line with other challenge studies in which healthy volunteers who received THC, either orally or intravenously, experienced a broad range of transient positive psychotic, negative psychotic and cognitive symptoms (Curran et al. 2002; D’Souza et al. 2004; Morrison et al. 2009). These studies also found that psychotic symptoms were not correlated with anxiety symptoms following THC. Significant increases in pulse rate occurred both in THC and placebo conditions, possibly due to the experimental conditions.

**Fig. 1.** Comparison of behavioural measures over time, in the \(\Delta^1\)-tetrahydrocannabinol (THC) condition: (a) Spielberger’s State-Trait Anxiety Inventory; (b) Addiction Research Centre Inventory; (c) Analogue Intoxication Scale; and (d) Visual Analogue Mood Scale (VAMS) tranquillization category. Data are means, with standard errors represented by vertical bars. Measurements were taken just before drug administration at baseline (0) and repeated 1, 2 and 3 h after drug administration. When conditioning on THC, a comparison of transiently psychotic and non-psychotic at 2 h after drug administration showed a significant difference in the VAMS tranquillization category only \((p = 0.03)\).
Table 2. Comparison of symptom scales between TP and NP groups at both baseline and 2 h

<table>
<thead>
<tr>
<th></th>
<th>Placebo</th>
<th>THC</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Mean difference between TP and NP (95% CI)</td>
<td>Z</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>STAI state</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baseline</td>
<td>−1.10 (−8.07 to 5.87)</td>
<td>−0.31</td>
</tr>
<tr>
<td>2 h</td>
<td>0.31 (−6.71 to 7.33)</td>
<td>0.09</td>
</tr>
<tr>
<td>ARCI</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baseline</td>
<td>2.83 (−0.94 to 6.60)</td>
<td>1.47</td>
</tr>
<tr>
<td>2 h</td>
<td>2.59 (−1.14 to 6.33)</td>
<td>1.36</td>
</tr>
<tr>
<td>AIS score</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baseline</td>
<td>−0.06 (−1.70 to 1.59)</td>
<td>−0.07</td>
</tr>
<tr>
<td>2 h</td>
<td>0.24 (−1.34 to 1.83)</td>
<td>0.30</td>
</tr>
<tr>
<td>VAMS tranquilization</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baseline</td>
<td>−0.96 (−5.48 to 3.56)</td>
<td>−0.42</td>
</tr>
<tr>
<td>2 h</td>
<td>−0.43 (−4.88 to 4.02)</td>
<td>−0.19</td>
</tr>
<tr>
<td>PANSS positive</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baseline</td>
<td>−0.30 (−0.70 to 0.10)</td>
<td>−1.48</td>
</tr>
<tr>
<td>2 h</td>
<td>0.08 (−0.32 to 0.48)</td>
<td>0.40</td>
</tr>
<tr>
<td>PANSS negative</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baseline</td>
<td>−0.20 (−0.64 to 0.24)</td>
<td>−0.88</td>
</tr>
<tr>
<td>2 h</td>
<td>−0.02 (−0.46 to 0.43)</td>
<td>−0.08</td>
</tr>
<tr>
<td>PANSS general</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baseline</td>
<td>−0.19 (−1.11 to 0.73)</td>
<td>−0.41</td>
</tr>
<tr>
<td>2 h</td>
<td>0.48 (−0.44 to 1.40)</td>
<td>1.03</td>
</tr>
<tr>
<td>PANSS total</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baseline</td>
<td>−0.69 (−2.05 to 0.67)</td>
<td>−0.99</td>
</tr>
<tr>
<td>2 h</td>
<td>0.55 (−0.82 to 1.91)</td>
<td>0.78</td>
</tr>
</tbody>
</table>

TP, Transiently psychotic; NP, non-psychotic; THC, Δ⁹-tetrahydrocannabinol; CI, confidence interval; STAI, State-Trait Anxiety Inventory; ARCI, Addiction Research Centre Inventory; AIS, Analogue Intoxication Scale; VAMS, Visual Analogue Mood Scale; PANSS, Positive and Negative Syndrome Scale.

* Due to small sample size, multilevel model analyses were performed separately for THC and placebo. The only significant difference between the groups was seen in VAMS tranquilization (p = 0.03) and all PANSS subscales: PANSS negative (p ≤ 0.02) and the PANSS positive, general and total subscales (all p ≤ 0.001).

* p < 0.05.

Task performance

We found a process-specific effect of THC on the main inhibitory measure of the task (commission/inhibition errors), but not on the executive process of the task (mean reaction time to ‘go’ trials). Across all participants THC increased inhibition errors at a trend-level of significance. Furthermore, there was a significant group × drug interaction on this measure, where TPs made significantly more commission errors than NPs. This finding cannot be related to performance differences, as we modelled only the correct trials. The findings show, that the effect of THC on impairing go/no-go task performance is specific to the inhibitory process and that this effect is more pronounced in those who develop transient psychosis. Our participants seldom used cannabis, whilst previously both occasional and heavy users of cannabis have been shown to have increased reaction time with the stop signal task, which is considered to be indicative of poor impulse control to single doses of THC (Ramaekers et al. 2009). The finding of inhibition deficits in TPs is comparable with those reported in people with schizophrenia and bipolar disorder during the go/no-go task (Kiehl et al. 2000; Fleck et al. 2011). Higher impulsivity, inability to suppress irrelevant acts and being unaware of making errors are likely to originate from a poorly coordinated response inhibition system and may be associated with the formation of some of the psychotic symptoms.

Neural effects of go/no-go task

Even though in our previous study (Borgwardt et al. 2008) relative to placebo, THC attenuated activation in the right inferior frontal gyrus and the ACG, here we found that the activation of the specific motor response inhibition network occurred only with a lenient threshold. However, consistent with the results of previous studies (Borgwardt et al. 2008; Bhattacharyya et al. 2010), we have again found that THC significantly increased activation in the right hippocampus, tail of the caudate and insula. While the latter two are key areas of inhibition, the hippocampus is not (Chambers et al. 2009). These findings suggest...
increased brain-processing effort during an inhibition task in a more widespread manner involving brain regions other than the specific response inhibition network, as has been reported previously in subjects who use cannabis on a regular basis (Tapert et al. 2007; Roberts & Garavan, 2010). Our findings extend those previous findings by showing that the up-regulation effect of these areas is already observed in people who use cannabis seldomly and further support the view that THC may be disrupting the neural mechanisms involved with this task. Alternative neuroanatomic recruitment such as involvement of the STG, MTG and cerebellum have also been reported in a number of studies carried out on patients with bipolar disorder and schizophrenia during response inhibition tasks (Fleck et al. 2011; Hughes et al. 2012).

**Group effect**

The two groups differed inherently in terms of their task-related activation in the right MTG and the vermis of the cerebellum, independent of THC, which were reduced in the TPs. This is an interesting finding which implies a trait difference between the groups. As we excluded those with personal and family history of psychosis, it is unlikely that this finding reflects these factors. Additionally, the task we used does not normally involve the right MTG or the cerebellum. We can tentatively suggest that the differences we found may reflect a more general difference in participants’ vulnerability to transient psychosis or to inhibitory dyscontrol and could be related to variations in single nucleotide polymorphisms that are associated with an increased risk of psychosis. However, our sample was not large enough to investigate this. Some recent studies focusing on early identification of psychosis have reported that the right MTG is implicated in at-risk or high-risk groups (Fusar-Poli et al. 2010; Meijer et al. 2011). Grey matter loss in the cerebellum amongst first-onset psychosis patients has also been shown in a recent meta-analysis (Fusar-Poli et al. 2011). Other supporting evidence for the involvement

---

**Fig. 2.** Comparison of Positive and Negative Syndrome Scale (PANSS) subscales, between the transiently psychotic and non-psychotic groups under Δ²-tetrahydrocannabinol (THC) and placebo conditions: (a) positive symptoms; (b) negative symptoms; (c) general psychopathology; and (d) total score. Data are means, with standard errors represented by vertical bars. A comparison of transiently psychotic and non-psychotic participants 2 h after drug administration showed significant differences in the PANSS negative subscale ($p = 0.02$) and a highly significant difference in all other subscales (all $p < 0.001$). Note that the y-axes have different scales in the graphs.

---

**Z. Atakan et al.**
of this region to genetic vulnerability to psychosis is found in a recently reported study, when a significant three-way interaction between two susceptibility genes implicated in glutamate transmission (G72 and DAAO) and the diagnosis of psychosis was detected at the right MTG (Mechelli et al. 2012).

Differential neurophysiological processing of THC

Our other main finding was that, as hypothesized, THC had a different effect on brain function in participants who developed transient psychotic symptoms from those who did not. These effects were evident in the left PHG, an area that has been implicated in the pathophysiology of psychosis in post-mortem (McDonald et al. 2000), neuropsychological (Marvel et al. 2007), volumetric (Witthaus et al. 2009), functional (Wolf et al. 2007) and neurochemical (Stone et al. 2010) imaging studies. Effects in this region in relation to THC-induced psychosis are of particular interest because of the evidence that chronic cannabis use can impair memory (Battisti et al. 2010b). Our group had previously reported that THC increased parahippocampal activation bilaterally during an encoding task (Bhattacharyya et al. 2009) and attenuated it during an attentional salience task (Bhattacharyya et al. 2012b). Furthermore, structural and functional changes in the parahippocampal region are frequently identified in relation to cannabis use (Lorenzetti et al. 2010; Martin-Santos et al. 2010). The finding that attenuated left parahippocampal activity is observed only in the TPs, but not in the NPs, provides further support that this region may be implicated in psychoses.

Additional differences were evident in the left middle/superior temporal cortices and in the cerebellum, areas that are implicated as key regions in schizophrenia (for reviews, see Honea et al. 2005; Smieskova et al. 2010; Jardri et al. 2011). The STG, as well as the cerebellum, has been implicated in inhibitory control (Rubia et al. 2007). The increased inhibition error rate in the TP group together with the increased activation in these two inhibition-related areas may suggest that the TP group had to work harder to maintain their inhibitory capacity, which was still below the level of that in the NP group. Conversely, THC increased activation in the right MTG in the TPs, whilst it attenuated it in the NPs. It is interesting that this area is differentially activated between the groups whether or not THC was present. It is difficult to interpret the two findings in relation to one another as they involve different analyses involving the same region.

In all of these regions, the effect of THC on activation in the group that experienced psychotic symptoms was in the opposite direction to that in the group that did not develop psychotic symptoms. The underlying processes for this dissociated effect will require further research and replication. Interestingly, a ketamine challenge study with healthy volunteers also reported a compelling consistency between the task, region, symptom associations and those reported in patients with schizophrenia (Honey et al. 2008).
To our knowledge, the present study is the first to demonstrate neurobiological differences that may contribute to the differential sensitivity to the psychotogenic effects of cannabis in healthy participants. Our findings imply that there is an association between individual variability in brain response and subsequent transitory psychotic symptom formation. Even though THC only transiently produced psychotic symptoms in some, the brain regions that were up-regulated are also those critically implicated in schizophrenia. Whilst acknowledging that transient psychosis is not the same as a full-blown psychosis, there may be varying degrees of risk in response to the psychotogenic effects of THC. How THC modulates specific brain regions can also provide information on symptom formation. Given the size of the problem universally, similar studies with larger samples are required to understand the basis of differential neural responses to THC to inform the ongoing public health debate about the risks of cannabis use, as well as leading to the development of interventions designed to reduce its use, particularly targeting those most at risk.

**Limitations**

This study has a modest sample size. Studies of this type are logistically difficult when participants, who seldom use cannabis, are asked to attend more than one study session. However, we have used non-parametric, repeated-measures analyses to obtain more robust findings in order to compensate for the low numbers (Brammer et al. 1997; Bullmore et al. 1999).

---

### Coordinates of regions where THC attenuated* activation in the TP group only

<table>
<thead>
<tr>
<th>Size</th>
<th>Tal (x)</th>
<th>Tal (y)</th>
<th>Tal (z)</th>
<th>Side</th>
<th>Cerebral region</th>
</tr>
</thead>
<tbody>
<tr>
<td>10</td>
<td>-22</td>
<td>-59</td>
<td>-2</td>
<td>L</td>
<td>Parahippocampal/Fusiform gyri</td>
</tr>
<tr>
<td>21</td>
<td>-43</td>
<td>-59</td>
<td>-2</td>
<td>L</td>
<td>Middle temporal gyrus</td>
</tr>
<tr>
<td>28</td>
<td>32</td>
<td>-56</td>
<td>-13</td>
<td>R</td>
<td>Cerebellum/Fusiform gyrus</td>
</tr>
</tbody>
</table>

### Coordinates of region where THC increased* activation in the TP group only

<table>
<thead>
<tr>
<th>Size</th>
<th>Tal (x)</th>
<th>Tal (y)</th>
<th>Tal (z)</th>
<th>Side</th>
<th>Cerebral region</th>
</tr>
</thead>
<tbody>
<tr>
<td>12</td>
<td>51</td>
<td>-41</td>
<td>-13</td>
<td>R</td>
<td>Middle temporal gyrus</td>
</tr>
</tbody>
</table>

---

Fig. 4. Interaction between the transiently psychotic (TP) and non-psychotic (NP) groups and drug conditions [Δ³-tetrahydrocannabinol (THC) versus placebo]. Plots (a), (b) and (c) show that the administration of THC attenuated activation in the left parahippocampal gyrus/fusiform gyrus (a crosshair), left middle temporal gyrus/superior temporal sulcus (b crosshair) and right cerebellum/fusiform gyrus (c crosshair) in the TP group, whilst it increased activation in the same region in the NP group \( p = 0.01 \). Plot (d) shows that THC modulated activation by increasing it in the right middle temporal gyrus (d crosshair) in the TP group, whilst it attenuated it in the NP group \( p = 0.01 \). Data are means indexed by the mean sum of squares ratio, with standard errors represented by vertical bars. The left side of the brain is shown on the left side of the images. All coordinates in Talairach (Tal) space. * In the NP group THC did the reverse activity in these regions.
The use of PANSS is another limitation, as this scale is not designed for transient psychosis, even though our participants experienced frank hallucinations and delusions temporarily.

Supplementary material

For supplementary material accompanying this paper visit http://dx.doi.org/10.1017/S0033291712001924.

Acknowledgements

The present study was supported by a Joint Medical Research Council/Priory clinical research training fellowship to S.B. and support from the Psychiatry Research Trust, UK. We are grateful to Glynis Ivin (Department of Pharmacology, the Maudsley Hospital), for the storing, blinding procedure and dispensing of the THC and placebo.

Declaration of Interest

None.

References


Variation in the psychotogenic effects of Δ9-tetrahydrocannabinol 1265


